Coherus Biosimilar Used ‘Scientific Justification’ To Skip Switch Study, Still Get Interchangeability With Lucentis

 
• By Sue Sutter
  
Generate a summary of this article
Listen to this article
Beta

Information on mechanism of action, pharmacokinetics, immunogenicity and toxicity convinced the US FDA there was no risk in terms of safety or diminished efficacy of switching between Cimerli and the reference product, Genentech’s eye drug Lucentis.

Lucentis Biosimilar Drug review profile
Cimerli was not subject to a 'switching' study prior to earning an interchangeability nod. • Source: Shutterstock

Coherus BioSciences, Inc. and partner Bioeq IP AG provided “sufficient justification” that Cimerli (ranibizumab-eqrn), a biosimilar of Genentech, Inc.’s macular degeneration treatment Lucentis (ranibizumab), will produce the same clinical result in any given patient for each condition of use, the US Food and Drug Administration said in deciding to award an interchangeability designation in the absence of a “switching” study.

This scientific justification took into account information on mechanism of action, pharmacokinetics, immunogenicity and toxicity, the FDA said in a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews

  • data

    New EU Filings

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By Saba Afreen

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>